<DOC>
	<DOCNO>NCT00534833</DOCNO>
	<brief_summary>The present trial follow-up AL203 study ( NCT00343889 ) . Primary Objectives : To describe antibody persistence 15 18 month age booster effect dose DTaP-HB-PRP~T Tritanrix-HepB/Hib™ ( give concomitantly Oral Polio Vaccine [ OPV ] ) . Secondary Objective : To describe safety profile booster dose DTaP-HB-PRP~T Tritanrix-HepB/Hib™ administer concomitantly OPV vaccine group .</brief_summary>
	<brief_title>Immunogenicity Study Antibody Persistence Booster Effect DTaP-HB-PRP~T Combined Vaccine Tritanrix-HepB/Hib™</brief_title>
	<detailed_description>Study participant receive booster vaccination DTaP-HB-PRP~T Tritanrix-HepB/Hib™ either concomitantly Oral Polio Vaccine ( OPV ) follow completion three dose primary series DTaP-Hep B-PRP-T combine vaccine Tritanrix HepB/Hib™ , give concomitantly OPV . Participants receive booster dose vaccine receive primary series , concomitant dose OPV Study AL203 ( NCT00343889 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Toddler age 15 18 month age day inclusion ( range : 456 day 578 day age inclusive ) Participated AL203 study complete threedose primary series either DTaPHBPRP~T TritanrixHepB/Hib™ , OPV , 6 , 10 14 week age Informed consent form sign one parent legal representative appropriate ( independent witness mandatory parent illiterate ) Able attend schedule visit comply trial procedure Participation another clinical trial 4 week precede trial vaccination Planned participation another clinical trial present trial period Congenital acquire immunodeficiency , immunosuppressive therapy longterm ( 2 week ) systemic corticosteroid therapy within precede 3 month Known systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance Chronic illness stage could interfere trial conduct completion Blood bloodderived product receive last 3 month Any vaccination 4 week precede trial vaccination Vaccination plan 4 week follow trial vaccination Febrile ( temperature ≥ 38.0°C ) acute illness day inclusion History document diphtheria , tetanus , pertussis , Haemophilus influenzae type b , hepatitis B poliomyelitis infection ( ) ( confirm either clinically , serologically , microbiologically ) Vaccination vaccine contain diphtheria , tetanus , pertussis , Haemophilus influenzae type b , hepatitis B , poliovirus 3 type antigen since end primary series Thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination Serious adverse event relate vaccination AL203 study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Hepatitis B Hansenula ( HB )</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
</DOC>